ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2022.79.03ymj-16Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHВариация числа копий ДНК (14 онкоассоциированных генов) при немелкоклеточном раке легкогоDNA copy number variations (14 cancer-associated genes) in non-small cell lung cancerАль-НсоурР. Д.Al-NsourR. D.

Аль-Нсоур Рашед Д. – аспирант кафедры онкологии

Alnsour Rashed D. – postgraduate student of the Department of Oncology

xitrilis@mail.ruПетрусенкоН. А.PetrusenkoN. A.

Петрусенко Наталья Александровна – м.н.с.

Ростов-на-Дону

Petrusenko Natalya Alexandrovna – junior researcher

Rostov-on-Don

ОлексеенкоВ. В.OlekseenkoV. V.

Олексеенко Виктор Валентинович – д.м.н., доцент, зав. кафедрой

Olekseenko Victor V. – MD, Associate Professor, Head of the Departmen

МаксимовА. Ю.MaksimovA. Y.

Максимов Алексей Юрьевич – д.м.н., проф., зам. ген. директора

Ростов-на-Дону

Maksimov Alexey Yurievich – MD, Prof. Deputy Gen. Director

Rostov-on-Don

СтатешныйО. Н.StateshnO. N.

Статешный Олег Николаевич – врач-онколог

Ростов-на-Дону

Stateshny Oleg Nikolayevich – oncologist

Rostov-on-Don

Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»РоссияS.I. Georgievsky Medical Academy FSAI HE V.I. Vernadsky Crimea Federal UniersityRussian FederationФГБУ «НМИЦ онкологии» МЗ РФРоссияFSBI NMRС of oncology, Ministry of Health of the Russian FederationRussian Federation202202022025031116Copyright © Аль-Нсоур Р.Д., Петрусенко Н.А., Олексеенко В.В., Максимов А.Ю., Статешный О.Н., 20252025Аль-Нсоур Р.Д., Петрусенко Н.А., Олексеенко В.В., Максимов А.Ю., Статешный О.Н.Al-Nsour R.D., Petrusenko N.A., Olekseenko V.V., Maksimov A.Y., Stateshn O.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/16

Целью работы было изучение относительной копийности 14 онкоассоциированных генов (APC, AURCA, CCND1, GKN1, PIK3CA, NKX21, ERBB2, SOX2, EGFR1, BRCA1, BRCA2, TP63, CDKN2A, MDM2) в образцах опухолевой ткани легкого как потенциальных онкомаркеров рака легкого. Статистически значимые события изменения CNV (р<0,05) были зафиксированы нами для генов CCND1, GKN1, PIK3CA, EGFR1, SOX2, BRCA2, TP63, MDM2 в образцах плоскоклеточного рака и NKX2-1 в образцах аденокарциномы легкого. Таким образом, эти гены могут быть использованы в качестве дифференцирующих и диагностических биомаркеров при НМРЛ.

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers, 15-30% of which is squamous cell carcinoma, 54% is adenocarcinoma. The copy number variations (CNVs) as one of the factors affecting gene transcription activity is necessary to assess the role of genetic variation in pathological processes. The purpose of our study was to research the relative number of copies of 14 onco-associated genes: APC, AURCA, CCND1, GKN1, PIK3CA, NKX2-1, ERBB2, SOX2, EGFR1, BRCA1, BRСА2, TP63, CDKN2A, MDM2, in lung tissue samples as tumor markers of lung cancer. The study included 72 patients with Slavic and Crimean Tatar (Crimean) population, aged 46-78 (median 64) years with a diagnosis of lung cancer T1-1aN0-2M0-1 (stage I-IV). The relative copy number variation of genetic loci was assessed by the RT-qPCR method. In our study, statistically significant CNV change events (p<0.05) were recorded for the CCND1, GKN1, PIK3CA, EGFR1, SOX2, BRCA2, TP63, MDM2 genes in squamous cell carcinoma samples and NKX2-1 in lung adenocarcinoma samples. Thus, these genes can be used as differentiating and diagnostic biomarkers in NSCLC.

рак легкогоотносительная копийность геновплоскоклеточный рак легкогоаденокарцинома легкогобиомаркерыlung cancercopy number variationssquamous cell lung cancerlung adenocarcinomabiomarkersReferencesБиомаркеры для иммунотерапии немелкоклеточного рака легкого / Харагезов Д.А., Лазутин Ю.Н., Златник Е.Ю. [и др.] // Южно-Российский онкологич. журнал. - 2021;2(3):31-41 https://doi.org/10.37748/2686-9039-2021-2-3-4Biomarkers for non-small cell lung cancer immunotherapy / Kharagezov D.A., Lazutin Yu.N., Zlatnik E.Yu. [et all.] // South Russian Journal of Cancer. - 2021;2(3):31-41 https://doi.org/10.37748/2686-9039-2021-2-3-4Петрусенко Н.А. Мутации в генах BRCA1/2 у пациенток юга России с злокачественными новообразованиями яичников/ Петрусенко Н.А., Вереникина Е.В., Якубова Д.Ю., Тимошкина Н.Н. // Якутский медицинский журнал. – 2020. - №4(72), с.87-89. DOI 10.25789/YMJ.2020.72.21.Petrusenko N.A. Mutations in the BRCA1 / 2 genes in patients in the south of Russia with malignant neoplasms of the ovaries / Petrusenko N.A., Verenikina E.V., Yakubova D.Yu., Timoshkina N.N. // Yakut Medical Journal. - 2020. - No. 4 (72), p. 87-89. DOI 10.25789/YMJ.2020.72.21.Петрусенко Н.А. Изменение копийности генов в злокачественных опухолях шейки матки с эндофитной и экзофитной формами роста / Петрусенко Н.А., Никитина В.П., Спиридонова Д.А., Кечерюкова М.М. // Современные проблемы науки и образования. – 2019. – № 3.; URL: http://www.science-education.ru/ru/articleview?id=28981 (date of access: 04/26/2021).Petrusenko N.A. Changes in the copy number of genes in malignant tumors of the cervix with endophytic and exophytic forms of growth/Petrusenko N.A., Nikitina V.P., Spiridonova D.A., Kecheryukova M.M. // Modern problems of science and education. - 2019. - No. 3.; URL: http://www.science-education.ru/ru/articleview?id=28981 (date of access: 04/26/2021).Duruisseaux M, Esteller M. Lung cancer epigenetics: From knowledge to applications. Semin Cancer Biol. 2018 Aug;51:116-128. doi: 10.1016/j.semcancer.2017.09.005.Duruisseaux M, Esteller M. Lung cancer epigenetics: From knowledge to applications. Semin Cancer Biol. 2018 Aug;51:116-128. doi: 10.1016/j.semcancer.2017.09.005.Erdem J.S., Skuag V., Bakke P., Gulsvik A., Haugen A., Zienolddiny S. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. BMC Cancer. 2016;16:28. https://doi.org/10.1186/s12885-016-2061-3 .Erdem J.S., Skuag V., Bakke P., Gulsvik A., Haugen A., Zienolddiny S. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. BMC Cancer. 2016;16:28. https://doi.org/10.1186/s12885-016-2061-3 .Fukazawa T., Guo M., Ishida N., Yamatsuji T., Takaoka M., Yokota E., Haisa M., Miyake N., Ikeda T., Okui T., et al. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Sci. Rep. 2016;6:20113. doi: 10.1038/srep20113.Fukazawa T., Guo M., Ishida N., Yamatsuji T., Takaoka M., Yokota E., Haisa M., Miyake N., Ikeda T., Okui T., et al. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Sci. Rep. 2016;6:20113. doi: 10.1038/srep20113.Gamazon E.R., Stranger B.E. The Impact of Human Copy Number Variation on Gene Expression. Brief. Funct. Genom. 2015;14:352– 357. doi: 10.1093/bfgp/elv017.Gamazon E.R., Stranger B.E. The Impact of Human Copy Number Variation on Gene Expression. Brief. Funct. Genom. 2015;14:352– 357. doi: 10.1093/bfgp/elv017.Hokari S, Tamura Y, Kaneda A, et al. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer. Mol Oncol. 2020;14(2):277-293. doi:10.1002/1878-0261.12608.Hokari S, Tamura Y, Kaneda A, et al. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer. Mol Oncol. 2020;14(2):277-293. doi:10.1002/1878-0261.12608.Jabs V, Edlund K, König H, Grinberg M, Madjar K, Rahnenführer J, Ekman S, Bergkvist M, Holmberg L, Ickstadt K, Botling J, Hengstler JG, Micke P. Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS One. 2017 Nov 7;12(11):e0187246. doi: 10.1371/journal.pone.0187246.Jabs V, Edlund K, König H, Grinberg M, Madjar K, Rahnenführer J, Ekman S, Bergkvist M, Holmberg L, Ickstadt K, Botling J, Hengstler JG, Micke P. Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS One. 2017 Nov 7;12(11):e0187246. doi: 10.1371/journal.pone.0187246.Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev. 2021;35(9-10):575-601. doi:10.1101/gad.347872.120.Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes Dev. 2021;35(9-10):575-601. doi:10.1101/gad.347872.120.Lakshmanachetty S, Balaiya V, High WA, Koster MI. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling. Mol Cancer Res. 2019;17(6):1279-1293. doi:10.1158/1541-7786.MCR-18-1355.Lakshmanachetty S, Balaiya V, High WA, Koster MI. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling. Mol Cancer Res. 2019;17(6):1279-1293. doi:10.1158/1541-7786.MCR-18-1355.Li Q., Liu F., Zhang Y., Fu L., Wang C., Chen X., Guan S., Meng X. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2016;7:34520–34531. doi: 10.18632/oncotarget.9145.Li Q., Liu F., Zhang Y., Fu L., Wang C., Chen X., Guan S., Meng X. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2016;7:34520–34531. doi: 10.18632/oncotarget.9145.Martell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Köbel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol Oncol. 2020 Sep;158(3):776- 784. doi: 10.1016/j.ygyno.2020.06.506.Martell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Köbel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol Oncol. 2020 Sep;158(3):776- 784. doi: 10.1016/j.ygyno.2020.06.506.Potempa M., Jonczyk P., Zalewska-Ziob M. Molekularne uwarunkowania raka płuca. Onkol. Prak. Klin. 2014;10:199–211.Potempa M., Jonczyk P., Zalewska-Ziob M. Molekularne uwarunkowania raka płuca. Onkol. Prak. Klin. 2014;10:199–211.Rooney M., Devarakonda S., Govindan R. Genomics of squamous cell lung cancer. Oncologist. 2013;18:707–716. doi: 10.1634/theoncologist.2013-0063.Rooney M., Devarakonda S., Govindan R. Genomics of squamous cell lung cancer. Oncologist. 2013;18:707–716. doi: 10.1634/theoncologist.2013-0063.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.Turnbull C, Sud A, Houlston RS. Cancer genetics, precision prevention and a call to action. Nat. Genet. 2018;50:1212–1218. doi: 10.1038/s41588-018-0202-0.Turnbull C, Sud A, Houlston RS. Cancer genetics, precision prevention and a call to action. Nat. Genet. 2018;50:1212–1218. doi: 10.1038/s41588-018-0202-0.Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thorac Cancer. 2020;11(6):1512- 1521. doi:10.1111/1759-7714.13419.Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thorac Cancer. 2020;11(6):1512- 1521. doi:10.1111/1759-7714.13419.Yang Y, Lu T, Li Z, Lu S. FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer. Cell Adh Migr. 2020;14(1):82-95. doi:10.1080/19336918.2020.1766308.Yang Y, Lu T, Li Z, Lu S. FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer. Cell Adh Migr. 2020;14(1):82-95. doi:10.1080/19336918.2020.1766308.Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun;5(3):288- 300. doi: 10.21037/tlcr.2016.06.07.Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun;5(3):288- 300. doi: 10.21037/tlcr.2016.06.07.

The authors declare that there are no conflicts of interest present.